Advancing Desmoid Tumor Science
The DTRF funds research that will advance current scientific knowledge about desmoid tumors, moving toward the development of new treatment options and bringing us closer to our ultimate goal of a cure for each and every patient with a desmoid tumor. Typically, the Foundation is particularly interested in innovative and translational research projects and will consider applications across the spectrum of research from basic science to clinical trials and correlative studies.
In 2024, we’ll be using a more targeted approach. Learn more about current grant cycle below.
Application Information
The Desmoid Tumor Research Foundation (DTRF) is pleased to announce that our 2024 grant cycle is open.
At the September 2023 DTRF International Research Workshop and DTRF Scientific & Medical Advisory Board meeting, a key research priority was identified: learning why some desmoid tumors spontaneously regress.
The 2024 grant cycle is for a planning grant to develop teams and/or preliminary data toward a larger grant to address questions around spontaneous tumor regression. Please read the RFP guidelines below for more information.
Full Application Deadline: Friday, June 14, 2024
View DTRF 2024 Request for Proposals
Please direct any questions to us at grants@dtrf.org.
Forms for Reports (For Current Grantees)
DTRF Progress Report Requirements
Desmoid Cell Line at ATCC
Publicly available desmoid tumor immortal cell lines are now available for purchase at ATCC, a public biorepository based in Manassas, VA. These tumor-derived models can be used in basic research as well as pharmacological screening applications. Detailed information about these models can be found on the ATCC website and on the HCMI website. Discounted pricing is available to academic researchers.
Continue Exploring
Clinicians & Researchers Newsletter
Receive monthly updates about treatment advances, grant applications, clinical trials, CME opportunities, and more.